RxDoctor Payments DataLook up a doctor →

Steven Brown, DO

Endocrinology, Diabetes & Metabolism · Layton, UTNPI 1649615873

Payments from drug & device makers

$104,951in general payments, 2019–2025

Across 713 payments — averaging $147.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$54K
  • Corcept Therapeutics$30K
  • Ascendis Pharma Endocrinology Inc$13K
  • Novo Nordisk$1K
  • Abbott$963
  • Amgen$856
  • plus $5K from 47 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC79$54,301
Corcept Therapeutics72$29,551
Ascendis Pharma Endocrinology Inc17$12,862
Novo Nordisk115$1,053
Abbott80$963
Amgen(2 entities)33$856
Lilly USA, LLC55$825
Xeris Pharmaceuticals, Inc.42$764
Tandem Diabetes Care, Inc.29$586
Dexcom, Inc.33$473
Antares Pharma, Inc.14$252
Boehringer Ingelheim14$237
Novartis11$225
AbbVie14$215
Insulet Corporation9$156
Medtronic(2 entities)9$139
AstraZeneca9$127
Amryt Pharma Holdings Ltd6$113
Amarin Pharma, Inc.5$83
BD4$81
Merck5$75
Lifescan, Inc.4$67
Recordati_rare_diseases_inc.2$64
Zealand Pharma US, Inc.4$59
Johnson & Johnson3$56
Pfizer3$55
Ascensia Diabetes Care US Inc.3$52
BETA Bionics, Inc.3$50
Radius Health, Inc.3$50
Bayer3$49
Stryker1$43
Kyowa Kirin, Inc.2$40
Halozyme Inc2$40
Shire North American Group Inc2$36
Sequel Med Tech, LLC2$35
Astellas Pharma US Inc2$32
Ultragenyx Pharmaceutical Inc.2$28
Embecta Corp.1$26
Eisai Inc.2$26
OPKO Pharmaceuticals, LLC1$21
Chiesi USA, Inc.1$19
Cequr Corporation1$18
EUSA Pharma (US) LLC1$17
Amphastar Pharmaceuticals, Inc.1$17
Neurocrine Biosciences, Inc.1$16
Acella Pharmaceuticals, LLC1$16
Endo Pharmaceuticals Inc.1$14
GRT US Holding, Inc.1$14
Amneal Pharmaceuticals LLC1$13
Ipsen Biopharmaceuticals, Inc1$12
Sobi, Inc1$11
Boston Scientific1$11
Arbor Pharmaceuticals, Inc.1$11

How this compares

$104,951 in reported general payments places this provider in the 85th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.

See all endocrinology, diabetes & metabolism providers in Utah →

Medicare billing

Part B allowed, 2024
$135,085
Medicare patients
252
Services billed
4,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Layton

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →